BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Gilead Sciences, Inc. (GILD) Stops Development of PAH Drug After Missing Study Goal


8/22/2012 6:47:40 AM

San Francisco Business Times by Ron Leuty, Reporter

Gilead Sciences Inc.'s heart and lung disease drug cicletanine failed a mid-stage trial, Dow Jones reported Tuesday, and the company is discontinuing development of the drug.

Foster City-based Gilead (NASDAQ: GILD) picked up cicletanine, aimed at pulmonary arterial hypertension patients, for an initial $10.9 million in May 2008 from Navitas Assets LLC.

The 162-patient Phase II study, listed as "terminated" on the Clinicaltrials.gov website, tested cicletanine against a placebo. It looked at how far patients could walk in six minutes after 12 weeks of treatment.

The study enrolled patients at 56 sites.

Patients with pulmonary arterial hypertension have continuous high blood pressure in the pulmonary artery that carries blood from the right ventricle in the heart to the small arteries in the lungs. In PAH patients, the passages narrow and thicken, and scar tissue and blood clots can form, often leading to failure on the right hand side of the heart.

There are treatments for PAH, including the Gilead drug Letairis, but the disease has no cure. Nearly 1,000 new cases of PAH are diagnosed each year in the United States.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES